Switch to:
Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
Research and Development
$1,467 Mil (TTM As of Mar. 2015)

This is the expense the company spent on research and development. Teva Pharmaceutical Industries Ltd's research and development for the three months ended in Mar. 2015 was $332 Mil. Its research and development for the trailing twelve months (TTM) ended in Mar. 2015 was $1,467 Mil.


Definition

This is the expense the company spent on research and development.

Teva Pharmaceutical Industries Ltd Research & Development for the trailing twelve months (TTM) ended in Mar. 2015 was 344 (Jun. 2014 ) + 412 (Sep. 2014 ) + 379 (Dec. 2014 ) + 332 (Mar. 2015 ) = $1,467 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.


Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Related Terms

Gross Profit


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

Teva Pharmaceutical Industries Ltd Annual Data

Dec05Dec06Dec07Dec08Dec09Dec10Dec11Dec12Dec13Dec14
Research & Development 3694955812,1888029511,0951,3561,4271,488

Teva Pharmaceutical Industries Ltd Quarterly Data

Dec12Mar13Jun13Sep13Dec13Mar14Jun14Sep14Dec14Mar15
Research & Development 442329339348411353344412379332
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GuruFocus Premium Plus Membership

FEEDBACK